多西他赛联合阿帕替尼二线治疗非鳞癌非小细胞肺癌的效果观察

Effect of docetaxel combined with apatinib as second-line therapy on non-squamous non-small cell lung cancer

目的分析多西他赛联合阿帕替尼二线治疗非鳞癌非小细胞肺癌(NSCLC)患者的效果。方法队列研究。抽取2022年3月至2023年3月新乡市中心医院收治的80例非鳞癌NSCLC患者,按照随机数字表法分为单一组和联合组,每组40例。单一组二线治疗给予多西他赛治疗,联合组二线治疗在单一组基础上联合阿帕替尼治疗。比较两组疾病控制率、免疫功能[分化簇4(CD4^(+))、分化簇3(CD3^(+))、分化簇8(CD8^(+))]水平、肿瘤标志物[血管内皮生长因子(VEGF)、糖类抗原125(CA125)、基质金属蛋白酶9(MMP-9)]水平及不良反应发生率。结果联合组疾病控制率(50.00%,20/40)高于单一组(27.50%,11/40),P<0.05。治疗后,联合组CD3^(+)、CD4^(+)水平高于单一组,CD8^(+)水平低于单一组(P<0.05);治疗后,联合组MMP-9、CA125、VEGF水平均低于单一组(P均<0.05)。两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论对非鳞癌NSCLC患者予以多西他赛联合阿帕替尼二线治疗,能够提升疾病控制率,增强免疫功能,降低肿瘤标志物水平,安全性可靠。

Objective To analyze the treatment effect of docetaxel combined with apatinib as second-line treatment on patients with non-squamous non-small cell lung cancer(NSCLC).Methods A total of 80 patients with non-squamous NSCLC admitted to Xinxiang Cen Hospital from March 2022 to March 2023 were selected for the cohort study.And they were divided into the single group and the combination group by the random number table method,with 40 cases in each group.The single group received docetaxel treatment,and the combination group received apatinib based on the treatment of the single group.Disease control rate,level of immune function evaluated by cluster of differentiation 4^(+)(CD4^(+)),cluster of differentiation 3^(+)(CD3^(+))and cluster of differentiation 8^(+)(CD8^(+)),the tumor markers,including vascular endothelial growth factor(VEGF),carbohydrate antigen 125(CA125)and matrix metalloproteinase-9(MMP-9),and the incidence of adverse reactions were compared between the two groups.Results The disease control rate of the combination group was 50.00%(20/40),higher than the 27.50%(11/40)of the single group(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in combination group were higher than those in single group,and the level of CD8^(+)was lower than that in the single group(P<0.05).After treatment,the levels of MMP-9,CA125 and VEGF in the combination group were lower than those in the single group(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Docetaxel combined with apatinib as second-line therapy for non-squamous NSCLC can improve disease control rate,enhance immune function of patients,and reduce levels of tumor markers,with reliable safety.